BioNeurology Products and Pipeline
Neurodegenerative DiseasesAlzheimer's Disease Abeta Aggregation Inhibitors(with Transition Therapeutics)
Discovery Phase:
Scientific research conducted with the aim of developing a drug for a specific disease or medical condition.
Preclinical Phase:
Animal studies and laboratory tests to evaluate safety and efficacy, demonstrate activity of a product candidate and identify its chemical and physical properties.
Phase 1:
Clinical studies to test safety profile of drug in humans.
Phase 2:
Clinical studies conducted with groups of patients to determine preliminary efficacy, dosage and expanded evidence of safety.
Phase 3:
Large scale clinical studies conducted in patients to provide sufficient data for statistical proof of efficacy and safety.
Filed Phase:
Filed
Approved Phase:
Approved
Marketed Phase:
Marketed |
Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Filed | Approved | Marketed |
| ELND005 | ||||||||
| Alzheimer's Disease Secretase Inhibitors | ||||||||
| Beta Secretase Research | ||||||||
| Gamma Secretase Research | ||||||||
| Gamma Secretase Inhibitor (ELND007) | ||||||||
| Gamma Secretase Inhibitor (ELND006) | ||||||||
| Parkinson's Disease | ||||||||
| Parkinson's Research | ||||||||
Autoimmune Diseases |
||||||||
| Multiple Sclerosis (with Biogen Idec) | ||||||||
| TYSABRI® (natalizumab) (U.S.) | ||||||||
| TYSABRI® (natalizumab) (EU) | ||||||||
| TYSABRI® Subcutaneous | ||||||||
| Crohn's Disease (with Biogen Idec) | ||||||||
| TYSABRI® (natalizumab) (U.S.) | ||||||||
| Multiple Myeloma (with Biogen Idec) | ||||||||
| TYSABRI® (natalizumab) | ||||||||
| Small Molecules natalizumab follow-ons | ||||||||
| ELND002 | ||||||||
| Autoimmune Research | ||||||||
Specialty Business |
||||||||
| Infectious Diseases | ||||||||
| MAXIPIME® (cefepime hydrochloride for injection) (U.S.) | ||||||||
Alzheimer's Immunotherapy Programi |
||||||||
| Bapineuzumab (AAB-001) Monoclonal Antibody Intravenous | ||||||||
| Bapineuzumab (AAB-001) Monoclonal Antibody Subcutaneous | ||||||||
| AAB-002 Monoclonal Antibody | ||||||||
| ACC-001 Immunoconjugate | ||||||||
Tip: Roll your mouse over the bars above to get an explanation of the phase they are at in the Pipeline.
Download Printer Friendly PDFi - JANSSEN Alzheimer Immunotherapy in collaboration with Pfizer. Elan retains an approximate one-quarter interest in the Alzheimer's Immunotherapy Program
TYSABRI is a registered trademark of Elan Pharmaceuticals, Inc. in the United States and of Elan Pharma International Ltd. in various countries outside the United States.
MAXIPIME is a registered trademark of Bristol-Myers Squibb Company and licensed exclusively in the U.S.to Elan Pharmaceuticals, Inc.
®2009 Elan Pharmaceuticals, Inc. ELN 022 0104